Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered common stock and pre-funded warrants offering by Aeglea, including the full exercise by the underwriters of their option to purchase additional shares of common stock. The common stock is listed on the Nasdaq Global Market under the symbol “AGLE.”

Based in Austin, Texas, Aeglea is a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Bryan M. Quinn and Travis B. Mitchell. The tax team included counsel Ethan R. Goldman and associate Rebecca A. Rosen. The intellectual property and technology transactions team included partner David R. Bauer and associate Yifu Chen. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post